– CGX-195 increased functional, secreted Z-A1AT and reduced polymerized Z-A1AT in cellular assays and in the PiZ mouse model – MONTREAL, Oct. 23, 2026 /PRNewswire/ -- Congruence Therapeutics ("Congruence"), a clinical-stage, computationally driven biotechnology company building a pipeline...
Hence then, the article about congruence therapeutics announces oral presentation on cgx 195 a novel small molecule aat corrector at the ers alpha 1 antitrypsin aat conference 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Congruence Therapeutics Announces Oral Presentation on CGX-195, a Novel Small Molecule AAT Corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026 )
Also on site :
- Dwayne Johnson and Oprah Winfrey gave $10 million to launch the People’s Fund of Maui for wildfire survivors
- In 2017, Jack Daniel’s named Nathan “Nearest” Green its first master distiller for teaching the brand’s founder to distill whiskey over a century earlier
- Clarks’ ‘Fabulous’ Fall-Ready Leather Loafers Are Cushioned for Bouncy Comfort, and They’re Now 40% Off